Merck & Co Inc (MRK)

MRK on New York Consolidated

60.55USD
23 Sep 2014
Price Change (% chg)

$-0.03 (-0.05%)
Prev Close
$60.58
Open
$60.15
Day's High
$60.73
Day's Low
$59.69
Volume
3,744,142
Avg. Vol
8,298,775
52-wk High
$61.33
52-wk Low
$44.62

MRK

Chart for MRK

About

Merck & Co., Inc. (Merck), is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceut... (more)

Overall

Beta: 0.42
Market Cap (Mil.): $174,751.00
Shares Outstanding (Mil.): 2,884.63
Dividend: 0.44
Yield (%): 2.91

Financials

  MRK Industry Sector
P/E (TTM): 31.93 33.02 33.86
EPS (TTM): 1.90 -- --
ROI: 6.92 18.15 17.39
ROE: 11.71 18.85 18.25
Search Stocks

Germany's Merck to buy Sigma-Aldrich for $17 billion to boost lab supplies operation

FRANKFURT - Drugs and chemicals maker Merck KGaA agreed on Monday to acquire U.S.-based Sigma-Aldrich Corp for $17 billion in cash to boost its lab supplies business, the biggest takeover in the German group's history.

22 Sep 2014

Deals of the day- Mergers and acquisitions

(Adds Trian Fund Management, Verizon, Endesa, TIM, Allianz, Sulzer, Perutnina Ptuj, Espirito Santo Financial Group, Falabella, UniCredit, Abertis, IAC/Interactive Corp, Hess Corporation, Merck & Co, PZU and Mediobanca)

17 Sep 2014

Merck licenses experimental psoriasis drug to India's Sun Pharma

- Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.

17 Sep 2014

Merck licenses experimental psoriasis drug to India's Sun Pharma

Sept 17 - Merck & Co Inc said it had licensed its experimental psoriasis drug to Indian generic maker Sun Pharmaceutical Industries Ltd for $80 million.

17 Sep 2014

Merck osteoporosis drug passes trial, but side effects hover

- Merck & Co said it will seek U.S. approval next year for its long-delayed experimental osteoporosis drug, odanacatib, after it proved effective in a late-stage trial but was associated with rare thigh-bone fractures seen with standard treatments.

15 Sep 2014

UPDATE 2-Merck osteoporosis drug passes trial, but side effects hover

(Adds Merck comment, details on side effects, effectiveness)

15 Sep 2014

Merck says osteoporosis drug achieves goal in large trial

Sept 15 - Merck & Co on Monday said it expects next year to seek U.S. approval for its experimental osteoporosis drug, odanacatib, after the once-weekly medicine met its primary effectiveness goals in a late-stage trial.

15 Sep 2014

UPDATE 2-S.Africa's Aspen to sell U.S. drug rights to Mylan for up to $300 mln

JOHANNESBURG, Sept 10 - Aspen Pharmacare is to sell the rights to market a blood clot drug in the United States to rival Mylan Inc for up to $300 million, it said on Wednesday, a move that would help Africa's top generic drugmaker pay down debt.

10 Sep 2014

BRIEF-Merck CEO says tax inversion deals would not fit its corporate strategy

Sept 9 - Merck & Co Inc : * Merck CEO, at Morgan Stanley Global Healthcare Conference, says tax inversion deals would not fit its corporate strategy * CEO says tax inversion benefit would require overly large transaction * CEO says changes needed to make U.S. tax rate more competitive, but may not

09 Sep 2014

Bristol-Myers sues Merck over U.S. immunotherapy patent

- Bristol-Myers Squibb Co on Thursday filed a lawsuit against Merck & Co Inc for allegedly infringing its immunotherapy patent. The company is seeking unspecified damages.

05 Sep 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks